A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.

Ciara ConduitIan D DavisJeffrey C GohGanessan KichenadasseHoward GurneyCarole A HarrisDavid PookLaurence KriegerFrancis ParnisCraig UnderhillDiana AdamsFelicia RoncolatoAnthony JoshuaTom FergusonPrashanth PrithvirajMichelle MorrisMichelle HarrisonStephen BegbieElizabeth HoveyMathew GeorgeElizabeth C LiowEmma K LinkMargaret McJannettCraig Gedyenull nullnull null

Published in: BJU international (2023)

Nivolumab monotherapy had a modest effect overall, with a few participants experiencing a long DOR. Sequential combination immunotherapy by addition of ipilimumab in the context of disease progression to nivolumab in nccRCC is not supported by this study, with only a minority of participants benefiting from this strategy.

Keyphrases

open label
randomized controlled trial